Venmax Drugs & Pharmaceuticals Limited's Board of Directors, at its meeting held on August 7, 2026, approved the unaudited standalone financial results for the quarter ended June 30, 2026, along with a Limited Review Report from statutory auditors PPKG & Co, Chartered Accountants, Hyderabad. The Board also approved the forfeiture of 7,80,001 partly paid-up Convertible Share Warrants on account of non-payment of the balance subscription amount by the concerned warrant holders.

Q1FY27 Financial Performance

Venmax Drugs and Pharmaceuticals recorded a significant year-on-year improvement in its top line and bottom line for the quarter ended June 30, 2026. Revenue from operations more than doubled to ₹247.94 lakhs from ₹121.03 lakhs in the corresponding quarter of the previous year. Total revenue, including other income of ₹0.03 lakhs, stood at ₹247.96 lakhs for the quarter. The following table presents a comparative view of key financial metrics (figures in ₹ lakhs):

Total expenses for Q1FY27 were ₹236.31 lakhs, compared to ₹117.29 lakhs in Q1FY26, with purchases of stock-in-trade being the largest component at ₹341.81 lakhs, partially offset by a favourable inventory change of ₹(116.99) lakhs. Profit before tax for the quarter was ₹11.65 lakhs, up from ₹3.74 lakhs in Q1FY26. Net profit for the period stood at ₹11.66 lakhs, against ₹3.74 lakhs in the year-ago quarter. Earnings per share (basic and diluted) improved to ₹0.10 from ₹0.07 in Q1FY26.

Balance Sheet Highlights

As at June 30, 2026, total assets stood at ₹1,682.64 lakhs, compared to ₹1,620.02 lakhs as at March 31, 2026. Current assets increased to ₹1,678.55 lakhs from ₹1,616.36 lakhs, driven primarily by a rise in inventories to ₹216.87 lakhs from ₹99.88 lakhs and other financial assets to ₹1,183.22 lakhs from ₹734.97 lakhs. Total equity improved to ₹1,500.78 lakhs from ₹1,411.62 lakhs, reflecting the period's profitability. Current liabilities declined to ₹181.80 lakhs from ₹203.34 lakhs over the same period.

Forfeiture of Share Warrants

In a significant corporate action, the Board approved the forfeiture of 7,80,001 partly paid-up Convertible Share Warrants that had been allotted on a preferential basis on March 20, 2025. The warrants were originally issued at ₹20/- per warrant, with 25% (₹5/- per warrant) collected upfront at the time of allotment and the balance 75% (₹15/- per warrant) payable upon exercise for conversion into equity shares. Of the total 1,00,25,000 warrants allotted, 92,44,999 warrants were duly converted into fully paid-up equity shares following receipt of the balance subscription amount. The remaining 7,80,001 warrants were forfeited after the respective holders failed to remit the balance amount despite demand letters and reminder notices issued by the Company.

Consequently, the upfront subscription amount of ₹39,00,005/- stands forfeited and retained by the Company. The details of the warrant holders whose warrants have been forfeited are as follows:

Following the forfeiture, the said warrants stand cancelled. The Company has stated it will deal with the forfeited warrants in accordance with the applicable provisions of the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and other applicable laws.

Auditor's Conclusion

Statutory auditors PPKG & Co, Chartered Accountants (FRN: 0009655S), Hyderabad, conducted a limited review of the unaudited standalone financial results for the quarter ended June 30, 2026, in accordance with Standard on Review Engagements (SRE) 2410 issued by the Institute of Chartered Accountants of India. The auditors expressed an unmodified conclusion, stating that nothing came to their attention indicating any material misstatement or non-disclosure as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The financial results are available on the Company's website at www.venmaxdrugs.com and on the BSE website at www.bseindia.com .

Venmax Drugs & Pharmaceuticals Limited has reported its audited standalone financial results for the quarter and year ended March 31, 2026, recording a return to profitability. The company posted a net profit of ₹24.82 lakh for the year, a reversal from the net loss of ₹1.05 lakh reported in the previous fiscal year. The Board of Directors approved the results at a meeting held on May 14, 2026. In compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published newspaper advertisements of the financial results in "Financial Express" and "Nava Telangana" on May 15, 2026. The financial results and audit report have also been made available on the company's website at www.venmaxdrugs.com .

The financial performance was driven by a substantial increase in operational scale. Revenue from operations for the year stood at ₹802.49 lakh, a sharp rise compared to ₹80.73 lakh in the corresponding period of the previous year. Total revenue, which includes other income, amounted to ₹818.53 lakh for the year ended March 31, 2026.

Financial Performance Overview

The company's expenses for the year totaled ₹790.83 lakh. Profit before tax for the year was recorded at ₹27.70 lakh, compared to a loss before tax of ₹1.41 lakh in the prior year. The Audit Committee reviewed and recommended the figures before the Board's approval. The following table summarises the key financial metrics for the reporting period:

Key Financial Metrics

Balance Sheet and Cash Flow

As of March 31, 2026, the company's total assets stood at ₹1620.02 lakh, a significant increase from ₹516.96 lakh in the previous year. This growth was largely attributed to a rise in current assets, which reached ₹1616.36 lakh. Equity share capital increased to ₹1158.29 lakh, bolstered by the conversion of 63,44,000 share warrants into equity shares during the year at a face value of ₹10 and a premium of ₹10 each.

Cash and cash equivalents decreased to ₹122.36 lakh as of March 31, 2026, from ₹248.24 lakh in the prior year. The net cash flow from operating activities was negative at ₹(1099.61) lakh, primarily due to changes in working capital. However, financing activities provided a net inflow of ₹973.73 lakh, largely driven by share application money pending allotment. The results were submitted to BSE Limited in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and were signed by Managing Director Venkata Rao Sadhanala (DIN: 02906370) from Hyderabad.